mRNA Poly(A) Tail Length Analysis Service
Among the critical quality attributes (CQAs), the polyadenosine (Poly(A)) tail at the 3' end plays a non-negotiable role in determining the molecule's fate. This homopolymeric stretch of adenosine residues is not merely a terminal sequence; it acts as a primary regulator of mRNA stability, protection against exonuclease-mediated degradation, and recruitment of the translation machinery. At CD BioGlyco, we recognize that even minor deviations in Poly(A) length lead to significant fluctuations in protein expression levels and therapeutic half-life. Our mRNA Poly(A) tail length analysis service provides a high-resolution, quantitative map of tail distribution. By leveraging advanced analytical platforms, we enable researchers to optimize mRNA vaccine candidates and gene therapy vectors, ensuring that every transcript is engineered for maximum potency and stability.
Key Technologies
- Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
By utilizing high-resolution mass spectrometry (HRMS) coupled with ion-pair reversed-phase liquid chromatography (IP-RP-HPLC), we achieve single-nucleotide resolution, allowing for the detection of subtle heterogeneity and non-adenosine modifications within the tail. - Capillary Electrophoresis (CE)
For high-throughput screening and routine quality control (QC), our CE platform offers rapid separation based on the charge-to-mass ratio. It provides a highly reproducible "molecular fingerprint" of the Poly(A) distribution. - Next-Generation Sequencing (NGS) Based Profiling
For complex samples requiring transcript-specific information, we utilize specialized NGS techniques. This approach allows us to correlate the Poly(A) tail length with the identity of specific mRNA isoforms.
Optimized mRNA Potency: mRNA Poly(A) Tail Length Analysis
As a pivotal component of our therapeutic nucleic acid development platform, CD BioGlyco offers an end-to-one structural characterization suite specifically designed for mRNA-based vaccine development. Our mRNA structural characterization services focus on the rigorous quantification of the Poly(A) tail, recognizing it as a vital determinant of vaccine efficacy. Our scope extends beyond simple length measurement.
- We provide a comprehensive analysis of the 3' end, including the determination of average tail length, the assessment of length distribution (heterogeneity), and the identification of 3' terminal modifications such as uridylation or guanylation that may signal transcript degradation.
- We utilize enzymatic digestion methods, such as RNase T1 or specialized DNAzymes, to selectively release the Poly(A) region from the large mRNA backbone, enabling precise downstream analysis without the interference of the high-molecular-weight coding sequence.
Whether you are working with in vitro transcribed (IVT) mRNA or samples extracted from biological matrices, our service is tailored to validate the success of your tailing strategies.
Workflow
Sample Quality Assessment and Pre-Processing
Upon receipt, every mRNA sample undergoes a rigorous intake QC. We assess purity and integrity using the bioanalyzer or fragment analyzer to ensure the RNA integrity number (RIN) meets the threshold for high-resolution structural analysis.
Site-Specific Enzymatic Fragmentation
Since intact mRNA is often too large for direct high-resolution MS analysis, we perform controlled enzymatic digestion. Using sequence-specific ribonucleases, we precisely cleave the mRNA to liberate the Poly(A) tail while keeping the coding region and untranslated regions (UTRs) separate.
Selective Enrichment of Poly(A) Fragments
To eliminate background noise from the coding sequence fragments, we utilize oligo(dT) magnetic bead capture or specialized chromatographic resins. This step ensures that the subsequent analytical signals are derived exclusively from the 3' tail population.
High-Resolution Analytical Separation
The enriched fragments are processed via IP-RP-HPLC or CE. Our optimized solvent systems and temperature controls prevent the formation of secondary structures, ensuring that the separation is purely dependent on the length of the adenosine chain.
Detection and Mass Profiling
The eluent is introduced into a high-resolution MS. Deconvolution algorithms are then applied to the raw mass spectra to determine the exact number of nucleotides in each sub-population of the tail.
Bioinformatic Analysis and Reporting
We generate distribution histograms, calculate the polydispersity index, and provide a detailed report that correlates the structural data with the expected biological performance of your mRNA candidate.
Publication Data
DoI: 10.1038/s41597-024-04226-8
Journal: Scientific Data
IF: 6.9
Published: 2025
Results: This study presents a comprehensive dataset on mRNA poly(A) tail composition and dynamics in mouse testes and ovaries, using Oxford Nanopore Direct RNA Sequencing (DRS) and Illumina RNA-seq. It focuses on wild-type mice and those with TENT5 polymerase knockouts (linked to infertility). The DRS method, paired with the Ninetails algorithm, enables accurate analysis of poly(A) tail length and non-adenosine residues (e.g., uridines, prevalent in testicular mRNAs near tail ends). Illumina data supplements differential gene expression insights. Key findings include uridine-enriched poly(A) tails in spermatogenesis-critical transcripts and TENT5c knockout impacts on germ cell gene expression.
Fig.1 Schematic representation of the non-adenosine analysis workflow. (Czarnocka-Cieciura, et al., 2025)
Applications
Vaccine Efficacy Optimization
By determining the optimal Poly(A) length that maximizes antigen expression, developers enhance the immunogenicity of mRNA vaccines while potentially reducing the required dosage.
mRNA Stability and Shelf-Life Studies
Our analysis identifies the rate of deadenylation under various storage conditions, providing critical data for the development of stable formulations and the establishment of expiration dating for biotherapeutics.
Gene Therapy Development
We ensure that the mRNA vectors possess the structural features necessary for sustained cytoplasmic persistence and efficient recruitment of the eukaryotic initiation factor 4F (eIF4F) complex.
Manufacturing Process Validation
We assist in validating the consistency of enzymatic polyadenylation versus template-encoded tailing, ensuring that the manufacturing process yields a uniform product that meets the specifications for identity and purity.
Advantages
Single-Nucleotide Resolution
Our LC-MS/MS platforms provide unmatched precision, allowing us to distinguish between tails differing by only one adenosine residue, ensuring the most accurate heterogeneity profiling available in the industry.
Flexible Analytical Platforms
We offer a choice between MS and NGS-based methods, allowing us to customize the approach based on your specific sample type, required throughput, and budget without compromising data quality.
Minimal Sample Requirement
CD BioGlyco generates comprehensive Poly(A) profiles from microgram or even nanogram quantities of mRNA, preserving your valuable therapeutic material for other critical assays.
Expert Data Interpretation
Our PhD-level scientists do not just provide raw data; we offer deep insights into how the observed Poly(A) distribution may impact your mRNA's stability and translational efficiency based on years of experience.
Frequently Asked Questions
Customer Review
"We were able to identify a sub-population of truncated tails that was negatively impacting our vaccine's expression levels. Their insights allowed us to refine our IVT process significantly."
– A.R., Senior Scientist
"Their technical team understands the nuances of mRNA structural characterization, and the LC-MS data was instrumental. Highly recommended for any nucleic acid therapeutic developer."
– E.T., Director of Analytical R&D
"We needed a rapid turnaround for a batch comparison study. The clarity of the reports and the depth of the statistical analysis made it easy for our team to make manufacturing adjustments."
– B.T., Principal Investigator
Associated Services
CD BioGlyco is committed to providing the most advanced analytical solutions for the burgeoning field of mRNA therapeutics. Our mRNA Poly(A) tail length analysis service stands at the intersection of cutting-edge technology and deep biological expertise, ensuring your candidates are built on a foundation of structural perfection. Please feel free to contact us for detailed information on our services or to request a formal quotation.
Reference
- Czarnocka-Cieciura, A.; et al. Comprehensive analysis of poly(A) tails in mouse testes and ovaries using Nanopore Direct RNA Sequencing. Scientific Data. 2025, 12: 43. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform


